Alfaddagh A, et al. - In this study with 218 patients with stable coronary artery disease receiving statins, researchers intended to define a target level of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to prevent coronary artery plaque progression. In a randomized manner, the participants were assigned to high-dose EPA and DHA (3.36 g daily) or no omega-3 for 30 months. They computed the omega-3 fatty acid index as EPA+DHA/total fatty acid. In nondiabetic subjects with mean LDL-C <80 mg/dL, coronary plaque progression was prevented by EPA and DHA added to statins when an index ≥4% was achieved. The nondiabetic subjects who were at risk of coronary plaque progression, despite statin therapy, were detected by low omega-3 index <3.43%. To maximize cardiovascular benefit, an omega-3 index ≥4% should be targeted.